Annual Report

2019

MorphoSys at a glance

Magazine

Taking big steps

MorphoSys is evolving. We talked to Chief Executive Officer Jean-Paul Kress about the challenges and opportunities facing the company.

READ STORY

Transatlantic Alliance

We take a look at how MorphoSys US is preparing for the potential tafasitamab launch. Tafasitamab is MorphoSys’ first proprietary drug candidate currently under FDA-review for approval to treat an especially difficult form of diffuse large B-cell lymphoma. In January 2020, the company signed a partnering deal with Incyte that will support MorphoSys to achieve its next goal – to co-commercialize tafasitamab in the United States.

READ STORY

Never losing sight of our goal

Our mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases.

READ STORY

Roadmap

2020 Priority Review for first own BLA and Incyte Partnership

The U.S. FDA accepts MorphoSys’ BLA submission for tafasitamab to treat r/r DLBCL in combination with lenalidomide for priority review. In addition, MorphoSys and Incyte sign a Collaboration and Licensing Agreement to further develop and commercialize tafasitamab globally, securing MorphoSys a $750 million upfront and a $150 million capital investment from Incyte

2019 New Leadership and Growth Towards Commercial Readiness

Jean-Paul Kress, M.D., a seasoned and highly experienced pharma executive with a strong commercial and operational track record, is appointed as new CEO of MorphoSys, effective September 1, 2019. Strengthening MorphoSys’ U.S. presence, the new U.S. headquarters in Boston are opened, home to MorphoSys’ growing commercial team and reflecting progress towards launch readiness for Tafasitamab.

2018 Nasdaq ipo and establishment of us presence

With the listing and IPO at Nasdaq in 2019, MorphoSys gains numerous new investors and strengthens its capital base (gross proceeds USD 239 million). In addition, the US subsidiary MorphoSys US Inc. is established to prepare the Company‘s planned commercialization for MOR208 subject to FDA approval.

2017 first approval

In 2017, MorphoSys‘s licensing partner Janssen receives approval for Tremfya® (guselkumab) for the treatment of moderate to severe plaque psoriasis in the United States, Europe and Canada. Approvals in other countries to follow.

2013 New partnerships for proprietary development

MorphoSys is increasingly entering into development and marketing partnerships with other biotech and pharmaceutical companies in order to advance its proprietary drug candidates. These include partnerships with GSK (2013 for MOR103), Merck (2014 for immunoncology), I-Mab Biopharma (2017 for MOR202 and 2019 for MOR210), Novartis (2019 for MOR106, together with Galapagos).

2010 development of MOR208

In 2010, MorphoSys signs a license agreement with Xencor Inc. for MOR208. In the same year, MorphoSys starts clinical development of the antibody. The first positive data on MOR208 where presented in 2012. In 2017, the U.S. Food and Drug Administration awarded MOR208 breakthrough therapy designation in the blood cancer indication of diffuse large B cell lymphoma (DLBCL). MorphoSys intends to develop MOR208 toward regulatory approval as soon as possible.

2008 Proprietary drug development

The first proprietary antibody MOR103 enters clinical development in 2008. In 2012, MorphoSys publishes positive study results with MOR103 in rheumatoid arthritis. The following year, MorphoSys signs a license agreement with GlaxoSmithKline for MOR103. In 2019, GlaxoSmith-Kline presents positive data from a phase 2 trial in rheumatoid arthritis patients.

2006 A novel agent against alzheimer‘s

In 2006 Partner Roche starts clinical development of a HuCAL antibody against Alzheimer‘s disease (gantenerumab). Six years later, gantenerumab became the first MorphoSys antibody to enter late stage clinical development (phase 3). In 2019, new phase 3 trials where initiated to evaluate and approve gantenerumab in an optimized dosage regimen.

2004 service and discovery partnerships

Initiation of a strategic partnership with Novartis in 2004, which expands into one of the largest antibody research collaborations in biotech and pharmaceuticals in 2007. MorphoSys has been researching and discovering antibodies on behalf of pharmaceutical partners since 1997. These include further partnerships with Bayer (1999), Roche (2000), Centocor (today: Janssen, 2000), Schering (2001) and Pfizer (2003).

2000 antibody technology

In 2000, MorphoSys presented its HuCAL antibody library. This was followed by the HuCAL Gold antibody library (2001) and the HuCAL PLATINUM antibody library (2008). Ylanthia, the next generation of antibody technologies, was launched in 2011. Slonomics, which has been part of the MorphoSys technology portfolio since 2010, enables the precise optimization of antibodies from the Ylanthia library.

1999 First ipo

MorphoSys AG goes public on the Frankfurt Stock Exchange in 1999. On September 6, 2004, the Company entered into the TecDAX and in 2019 to the MDAX.

1992 the beginning

Martinsried bei München.

The company was founded in Martinsried near Munich.

As a fully integrated biopharmaceutical company, we want to develop the medicine of tomorrow. Our interactive roadmap takes you on this path — click by click.

Start now
2020 Priority Review for first own BLA and Incyte Partnership

The U.S. FDA accepts MorphoSys’ BLA submission for tafasitamab to treat r/r DLBCL in combination with lenalidomide for priority review. In addition, MorphoSys and Incyte sign a Collaboration and Licensing Agreement to further develop and commercialize tafasitamab globally, securing MorphoSys a $750 million upfront and a $150 million capital investment from Incyte

Artboard Created with Sketch.
outlines Created with Sketch.
Artboard Created with Sketch.
2019 New Leadership and Growth Towards Commercial Readiness

Jean-Paul Kress, M.D., a seasoned and highly experienced pharma executive with a strong commercial and operational track record, is appointed as new CEO of MorphoSys, effective September 1, 2019. Strengthening MorphoSys’ U.S. presence, the new U.S. headquarters in Boston are opened, home to MorphoSys’ growing commercial team and reflecting progress towards launch readiness for Tafasitamab.

Artboard Copy Created with Sketch.
Artboard Copy Created with Sketch.
Artboard Created with Sketch.
2018 Nasdaq IPO and Establishment of U.S. Presence

With the listing and IPO at Nasdaq in 2019, MorphoSys gains numerous new investors and strengthens its capital base (gross proceeds USD 239 million). In addition, the US subsidiary MorphoSys US Inc. is established to prepare the Company‘s planned commercialization for MOR208 subject to FDA approval.

canvas Created with Sketch.
outlines Created with Sketch.
2017 First Approval

In 2017, MorphoSys‘s licensing partner Janssen receives approval for Tremfya® (guselkumab) for the treatment of moderate to severe plaque psoriasis in the United States, Europe and Canada. Approvals in other countries to follow.

2013 New Partnerships for Proprietary Development

MorphoSys is increasingly entering into development and marketing partnerships with other biotech and pharmaceutical companies in order to advance its proprietary drug candidates. These include partnerships with GSK (2013 for MOR103), Merck (2014 for immunoncology), I-Mab Biopharma (2017 for MOR202 and 2019 for MOR210), Novartis (2019 for MOR106, together with Galapagos).

canvas Created with Sketch.
outlines Created with Sketch.
canvas Created with Sketch.
outlines Created with Sketch.
2010 Development of MOR208

In 2010, MorphoSys signs a license agreement with Xencor Inc. for MOR208. In the same year, MorphoSys starts clinical development of the antibody. The first positive data on MOR208 where presented in 2012. In 2017, the U.S. Food and Drug Administration awarded MOR208 breakthrough therapy designation in the blood cancer indication of diffuse large B cell lymphoma (DLBCL). MorphoSys intends to develop MOR208 toward regulatory approval as soon as possible.

2008 Proprietary Drug Development

The first proprietary antibody MOR103 enters clinical development in 2008. In 2012, MorphoSys publishes positive study results with MOR103 in rheumatoid arthritis. The following year, MorphoSys signs a license agreement with GlaxoSmithKline for MOR103. In 2019, GlaxoSmith-Kline presents positive data from a phase 2 trial in rheumatoid arthritis patients.

canvas Created with Sketch.
outlines Created with Sketch.
canvas Created with Sketch.
outlines Created with Sketch.
2006 A Novel Agent Against Alzheimer‘s

In 2006 Partner Roche starts clinical development of a HuCAL antibody against Alzheimer‘s disease (gantenerumab). Six years later, gantenerumab became the first MorphoSys antibody to enter late stage clinical development (phase 3). In 2019, new phase 3 trials where initiated to evaluate and approve gantenerumab in an optimized dosage regimen.

2004 Service and Discovery Partnerships

Initiation of a strategic partnership with Novartis in 2004, which expands into one of the largest antibody research collaborations in biotech and pharmaceuticals in 2007. MorphoSys has been researching and discovering antibodies on behalf of pharmaceutical partners since 1997. These include further partnerships with Bayer (1999), Roche (2000), Centocor (today: Janssen, 2000), Schering (2001) and Pfizer (2003).

canvas Created with Sketch.
outlines Created with Sketch.
canvas Created with Sketch.
outlines Created with Sketch.
2000 Antibody Technology

In 2000, MorphoSys presented its HuCAL antibody library. This was followed by the HuCAL Gold antibody library (2001) and the HuCAL PLATINUM antibody library (2008). Ylanthia, the next generation of antibody technologies, was launched in 2011. Slonomics, which has been part of the MorphoSys technology portfolio since 2010, enables the precise optimization of antibodies from the Ylanthia library.

1999 First IPO

MorphoSys AG goes public on the Frankfurt Stock Exchange in 1999. On September 6, 2004, the Company entered into the TecDAX and in 2019 to the MDAX.

1992 The Beginning

Martinsried bei München.

The company was founded in Martinsried near Munich.

Our Goal: Is to develop MorphoSys into a Fully Integrated Biopharmaceutical Company.

Again
1 2 3 4 5 6 7 8 9 10

Downloads

Report (PDF) Further Downloads